Video
Author(s):
Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.
Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.
Patients with relapsed/refractory sarcoma have very limited treatment options, says Navai. Despite all of the trials that have been done over the past 40 years in osteosarcoma, there has been no improvement in survival. Although patients have access to chemotherapy and emerging targeted therapies, they have shown limited efficacy, she adds.
HER2 is expressed in some sarcomas and has been explored as a potential target, but it is not gene-amplified, as it is in breast cancer. The levels of surface expression are much lower, and a result, HER2-targeted antibodies have not shown any activity in this setting. CAR T-cell therapies, however, have the ability to detect HER2 mutations at significantly lower levels, concludes Navai.
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma
PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma
Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer
2 Commerce Drive
Cranbury, NJ 08512